8月5日，荣昌生物公告，预计2026年半年度营业收入约58.5亿元，同比增加约433%；归属于母公司所有者的净利润约47亿元，上年同期净亏损4.5亿元，实现扭亏为盈；扣非净利润约43亿元，亦实现扭亏为盈。
业绩增长主要因核心产品泰它西普、维迪西妥单抗国内销售收入持续增长，以及与艾伯维就RC148签署独家授权许可协议带来的技术授权收入大幅增加。
8月5日，荣昌生物公告，预计2026年半年度营业收入约58.5亿元，同比增加约433%；归属于母公司所有者的净利润约47亿元，上年同期净亏损4.5亿元，实现扭亏为盈；扣非净利润约43亿元，亦实现扭亏为盈。
业绩增长主要因核心产品泰它西普、维迪西妥单抗国内销售收入持续增长，以及与艾伯维就RC148签署独家授权许可协议带来的技术授权收入大幅增加。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.